The drug also showed a 32 percent reduction in all-cause mortality and 35 percent reduction in hospitalization for heart failure.
“These results are both novel and exciting for the millions of people living with type 2 diabetes at risk for cardiovascular disease,” said Bernard Zinman, lead investigator of the trial. “Addressing the burden of cardiovascular events, including death, is at the core of diabetes care, and until now no single diabetes medication has been associated with a reduction in mortality.”